The Board will need to raise additional funds to accomplish the following:
Also
To reach the late
preclinical stage common to the recent license deals listed above, EiRx will
require a minimum of two to three years' further research and development.
So more share dilution to come, and who the kcuk will wait around another 2/3 years. Also looks like ERX have done an about turn on these $18m milestone payments. Another irish company for the bin.